Janux Therapeutics, Inc. Stock Split Ratio
Janux Therapeutics, Inc. (JANX) reported Stock Split Ratio of 128.10% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2023-03-10
- Janux Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2022-03-31 was 128.10%.
- Janux Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2022 was 128.10%, a 0.00% change from fiscal 2021.
- Janux Therapeutics, Inc. stockholders' equity note, stock split, conversion ratio for fiscal 2021 was 128.10%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2022-12-31 | 128.10% 10-K · filed 2023-03-10 | |||
| 2022-03-31 | 128.10% 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | 128.10% 10-K · filed 2022-03-18 | |||
| 2021-09-30 | 128.10% 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | 128.10% 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |